×
About 190,458 results

ALLMedicine™ Prostate Cancer Center

Research & Reviews  87,587 results

A pharmacoeconomic evaluation of pharmaceutical treatment options for prostate cancer.
https://doi.org/10.1080/14656566.2021.1925647
Expert Opinion on Pharmacotherapy; Moussa M, Papatsoris A et. al.

Jun 2nd, 2021 - Prostate cancer is one of the most common neoplasms in men. For many years the mainstay of treatment was androgen deprivation therapy, but during last decade many novel agents have emerged, accompanied by increased costs for healthcare systems. In...

Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agent...
https://doi.org/10.3390/curroncol28030171
Current Oncology (Toronto, Ont.); Tu MM, Clemons M et. al.

Jun 2nd, 2021 - A cost-utility analysis was performed based on the Rethinking Clinical Trials (REaCT) bone-targeted agents (BTA) clinical trial that compared 12-weekly (once every 12 weeks) (n = 130) versus 4-weekly (once every 4 weeks) (n = 133) BTA dosing for m...

Diagnostic Performance of PI-RADS v2, Proposed Adjusted PI-RADS v2 and Biparametric Mag...
https://doi.org/10.3390/curroncol28030169
Current Oncology (Toronto, Ont.); Cai GH, Yang QH et. al.

Jun 2nd, 2021 - To evaluate the diagnostic performance of PI-RADS v2, proposed adjustments to PI-RADS v2 (PA PI-RADS v2) and biparametric magnetic resonance imaging (MRI) for prostate cancer detection. A retrospective cohort of 224 patients with suspected prostat...

Perceived barriers to the adoption of active surveillance in low-risk prostate cancer: ...
https://doi.org/10.1186/s12885-021-08386-3 10.1200/JCO.2015.62.5764 10.1001/jama.2015.12607 10.1093/jncimonographs/lgs040 10.1001/jamaoncol.2014.192 10.1002/cncr.29574 10.1001/jama.2015.6036 10.1016/j.juro.2008.06.019 10.1016/j.eururo.2014.08.024 10.1155/2017/1467056 10.1177/0272989X15597226 10.1016/j.juro.2015.05.093 10.1177/0272989X16662841 10.2147/PPA.S83333 10.1093/jncimonographs/lgs030 10.1002/pros.21406 10.3122/jabfm.2012.06.120128 10.1200/JCO.2006.09.9580 10.1111/bju.13651 10.1200/JCO.2007.13.2555 10.1038/pcan.2015.10 10.1200/JCO.2009.26.0133 10.1200/JOP.2015.007344 10.1016/j.healthpol.2006.03.001 10.1097/00005650-198308000-00004 10.2307/2137284 10.1111/j.1744-1609.2012.00253.x 10.1001/archinternmed.2009.521 10.1016/S1470-2045(06)70940-8 10.1177/1557988318785741 10.1016/j.cct.2006.08.009 10.1177/000271629956600105 10.1097/MLR.0000000000000155 10.1634/theoncologist.2015-0214 10.1186/s12913-018-3273-9 10.1200/JCO.2014.55.1192 10.1200/JCO.2014.59.2329 10.1097/JU.0000000000000621 10.1016/j.eururo.2012.05.037 10.1016/j.eururo.2013.05.049 10.1111/bju.13002 10.7326/0003-4819-156-8-201204170-00010 10.1016/j.pec.2011.03.012 10.1291/hypres.31.1765 10.1001/jamainternmed.2015.63 10.1186/s13012-016-0484-5 10.1377/hlthaff.2011.1372 10.1056/NEJMsa1201141 10.1001/jama.2013.6882 10.1093/jnci/djq417 10.1056/NEJMsa0910784 10.1016/j.urology.2012.12.044 10.1186/s12894-015-0020-y 10.1016/j.juro.2016.02.2963 10.1002/cncr.21822 10.1097/COC.0b013e3181b215d5
BMC Cancer; Ellis SD, Hwang S et. al.

Jun 1st, 2021 - Clinical practice guidelines recommend active surveillance as the preferred treatment option for low-risk prostate cancer, but only a minority of eligible men receive active surveillance, and practice variation is substantial. The aim of this stud...

see more →

Guidelines  393 results

ASTRO Editorial: The AUA-ASTRO-SUO Advanced Prostate Cancer Guidelines: A Continued but...
https://doi.org/10.1016/j.prro.2020.10.002
Practical Radiation Oncology; Zietman AL,

Dec 14th, 2020 - ASTRO Editorial: The AUA-ASTRO-SUO Advanced Prostate Cancer Guidelines: A Continued but Changing Role for the Radiation Oncologist.|2020|Zietman AL, ,|

Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART II.
https://doi.org/10.1097/JU.0000000000001376
The Journal of Urology; Lowrance WT, Breau RH et. al.

Sep 22nd, 2020 - The summary presented herein represents Part II of the two-part series dedicated to Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline discussing prognostic and treatment recommendations for patients with castration-resistant disease. Please refer ...

Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I.
https://doi.org/10.1097/JU.0000000000001375
The Journal of Urology; Lowrance WT, Breau RH et. al.

Sep 22nd, 2020 - The summary presented herein represents Part I of the two-part series dedicated to Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline discussing prognostic and treatment recommendations for patients with biochemical recurrence without metastatic di...

American Society for Radiation Oncology Editorial: Rapidly Evolving Technologies Relate...
https://doi.org/10.1016/j.prro.2020.06.009
Practical Radiation Oncology; Bauman GS, Jani AB

Sep 6th, 2020 - American Society for Radiation Oncology Editorial: Rapidly Evolving Technologies Related to Imaging Strategies for Advanced Prostate Cancer.|2020|Bauman GS,Jani AB,|

Optimizing the management of castration-resistant prostate cancer patients: A practical...
https://doi.org/10.1002/pros.24053
The Prostate REFERENCES; Shore ND, Drake CG et. al.

Aug 11th, 2020 - Advanced prostate cancer (PC) patients, especially those with metastatic prostate cancer (mPC), often require complex management pathways. Despite the publication of clinical practice guidelines by leading urological and oncological organizations ...

see more →

Drugs  341 results see all →

Clinicaltrials.gov  95,387 results

Genetic Analysis Shows Race-Specific Tumor Alterations Tied to Racial Disparities in Prostate Cancer
https://www.medscape.com/viewarticle/952801

Jun 9th, 2021 - NEW YORK (Reuters Health) - Tumor genomic factors differed substantially between African-American men (AAM) and European-American men (EAM) who underwent radical prostatectomy, potentially revealing a basis for racial disparity in prostate cancer,...

NICE Publishes Draft Guidance Recommending Enzalutamide for Prostate Cancer
https://www.medscape.com/viewarticle/952659

Jun 7th, 2021 - The National Institute for Health and Care Excellence (NICE) has published draft guidance on the use of the androgen receptor inhibitor enzalutamide (Xtandi, Astellas), plus androgen deprivation therapy (ADT), as an option for treating prostate ca...

A pharmacoeconomic evaluation of pharmaceutical treatment options for prostate cancer.
https://doi.org/10.1080/14656566.2021.1925647
Expert Opinion on Pharmacotherapy; Moussa M, Papatsoris A et. al.

Jun 2nd, 2021 - Prostate cancer is one of the most common neoplasms in men. For many years the mainstay of treatment was androgen deprivation therapy, but during last decade many novel agents have emerged, accompanied by increased costs for healthcare systems. In...

Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agent...
https://doi.org/10.3390/curroncol28030171
Current Oncology (Toronto, Ont.); Tu MM, Clemons M et. al.

Jun 2nd, 2021 - A cost-utility analysis was performed based on the Rethinking Clinical Trials (REaCT) bone-targeted agents (BTA) clinical trial that compared 12-weekly (once every 12 weeks) (n = 130) versus 4-weekly (once every 4 weeks) (n = 133) BTA dosing for m...

see more →

News  6,583 results

Genetic Analysis Shows Race-Specific Tumor Alterations Tied to Racial Disparities in Prostate Cancer
https://www.medscape.com/viewarticle/952801

Jun 9th, 2021 - NEW YORK (Reuters Health) - Tumor genomic factors differed substantially between African-American men (AAM) and European-American men (EAM) who underwent radical prostatectomy, potentially revealing a basis for racial disparity in prostate cancer,...

NICE Publishes Draft Guidance Recommending Enzalutamide for Prostate Cancer
https://www.medscape.com/viewarticle/952659

Jun 7th, 2021 - The National Institute for Health and Care Excellence (NICE) has published draft guidance on the use of the androgen receptor inhibitor enzalutamide (Xtandi, Astellas), plus androgen deprivation therapy (ADT), as an option for treating prostate ca...

'Major Milestone' in mCRPC: Radiopharmaceutical Boosts Survival
https://www.medscape.com/viewarticle/952350

Jun 2nd, 2021 - A novel radiopharmaceutical has been shown to boost survival when added to standard treatment for patients with metastatic castration-resistant prostate cancer (mCRPC) whose disease had progressed after chemotherapy and the use of androgen inhibit...

NICE Draft Guidance on Apalutamide Plus ADT for Prostate Cancer
https://www.medscape.com/viewarticle/951959

May 27th, 2021 - New draft guidance from the National Institute for Health and Care Excellence (NICE) suggests apalutamide plus androgen deprivation therapy (ADT) will not be approved as a treatment for hormone-sensitive metastatic disease prostate cancer or hormo...

New Agent Approved for PSMA PET Scanning in Prostate Cancer
https://www.medscape.com/viewarticle/952010

May 26th, 2021 - A new injectable radioactive diagnostic agent for positron-emission tomography (PET) imaging for men with prostate cancer has been approved by the US Food and Drug Administration (FDA). The agent, piflufolastat F 18 (PYLARIFY), is a fluorinated sm...

see more →

Patient Education  167 results see all →